Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31.2M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
15.1M
-
Shares change
-
-32.7K
-
Total reported value, excl. options
-
$144M
-
Value change
-
-$326K
-
Number of buys
-
19
-
Number of sells
-
-13
-
Price
-
$9.56
Significant Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q3 2023
44 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.1M shares
of 31.2M outstanding shares and own 48.35% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (4.81M shares), PERCEPTIVE ADVISORS LLC (3.01M shares), Sands Capital Ventures, LLC (1.65M shares), CITADEL ADVISORS LLC (1.65M shares), WELLINGTON MANAGEMENT GROUP LLP (888K shares), MARSHALL WACE, LLP (597K shares), BlackRock Inc. (529K shares), VANGUARD GROUP INC (468K shares), NEA Management Company, LLC (430K shares), and FEDERATED HERMES, INC. (226K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.